Anxiety News and Research

Latest Anxiety News and Research

Subconscious change of heart could happen in response to failure in a competitive situation

You may think of your love for your mate as the noble emotion of a pure heart, but some primitive parts of your brain are taking a decidedly more pragmatic approach to the subject, according to Stanford biologists.

25 Nov 2010

USFDA grants Sun Pharma tentative marketing approval for generic Cymbalta

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules.

24 Nov 2010

Study reveals few advantages of prenatal diagnosis of cleft lip and palate

Many expectant parents look forward to routine ultrasounds as their first opportunity to "see" their baby. But the ultrasound can reveal that the fetus has unexpected medical conditions, such as a diagnosis of cleft lip and palate. Despite the emotional distress the diagnosis can bring, it can also offer the opportunity to prepare for the child's future needs. However, a study has found little difference between mothers who were given a prenatal diagnosis of cleft lip and palate and those who discovered the problem at birth.

24 Nov 2010

Ziconotide could promote suicidal tendencies in vulnerable patients: Research

24 Nov 2010

Study finds solution for debate about mutation testing to prevent children with cystic fibrosis

Testing for genetic mutations beyond those medically recommended is unlikely to prevent the birth of children with classic cystic fibrosis and may detect mutations causing only mild disease, according to a study published online in Genetics in Medicine, the official publication of the American College of Medical Genetics (ACMG).

From Quest Diagnostics 24 Nov 2010

Experience of ill health associated with reduction or cessation of alcohol consumption

In a cross-sectional study from the 2004 and 2007 Australian National Drug Strategy Household (NDSH) surveys, respondents were questioned about their current and past drinking, the presence of formal diagnosis for specific diseases (heart disease, type 2 diabetes, hypertension, cancer, anxiety, depression) and self-perceived general health status. The sample sizes for the 2004 and 2007 NDSH surveys were 24,109 and 23,356, respectively.

24 Nov 2010

Ziconotide could promote suicidal tendencies: Study

The active agent ziconotide, the synthetic toxin of the cone snail (Conus magus), was acclaimed a safe alternative to morphine when it was introduced six years ago. Now it is increasingly suspected of causing patients to commit suicide. Researchers working under the auspices of Prof. Christoph Maier (Director of the Pain Clinic Bergmannsheil at the Ruhr University in Bochum) presume that ziconotide not only suppresses the transmission of pain stimuli, but also deteriorates the frame of mind and could simultaneously reduce anxiety and impulse control.

23 Nov 2010

AADA releases updated position statement on isotretinoin usage

The American Academy of Dermatology Association (AADA) recently updated its position statement on the use of isotretinoin. The position continues to state that patient safety is dermatologists' primary concern and that the AADA is committed to the safe and responsible use of isotretinoin, which is the most effective treatment for severe acne.

23 Nov 2010

Australian university students a ‘stressed out’ bunch: Study

According to the latest findings the rates of serious mental illness are more than five times higher among university students than in the general population. The study conducted by researchers at University of Queensland was published in the latest issue of Australian Psychologist. It also found that rate of pyschological distress among university students is almost three times higher than in the general population.

22 Nov 2010

FDA grants Impax tentative approval for generic Cymbalta NDA

Impax Laboratories, Inc. confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application for generic version of Cymbalta® delayed-release (duloxetine hydrochloride) 20, 30 and 60 mg capsules.

22 Nov 2010

Neurocrine announces results from elagolix Phase II Daisy PETAL study in endometriosis

Neurocrine Biosciences, Inc. today announced results from the open-label portion of the six month Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

22 Nov 2010

Simple strategies to cope with holiday stress

Dr. Richard Blonna, author, life coach, and stress management expert, offers five simple strategies for managing holiday stress. His approach to managing the worry and anxiety associated with holiday stress is adapted from his new book, Stress Less, Live More; How Acceptance and Commitment Therapy Can Help You Live a Busy Yet Balanced Life.

20 Nov 2010

Children with severe congenital heart defects show high risk of emotional reactivity

Research from the Norwegian Institute of Public Health (NIPH) shows that children with severe congenital heart defects have twice the risk of anxiety at 18 months of age compared to healthy children. Children with mild and moderate heart defects, on the other hand, did not show an increased risk of anxiety.

18 Nov 2010

Back pain sufferers get quicker diagnosis and treatment when examined by Nurse Practitioner

Results of a Toronto Western Hospital study show that patients suffering back pain get quicker diagnosis and treatment when a Nurse Practitioner conducts the first examination. Traditionally, patients face long and anxiety-ridden wait times - up to 52 weeks - before an initial examination by a spine surgeon. Results from the year long TWH study showed wait times for patients examined by a Nurse Practitioner were significantly shorter, ranging from 10 to 21 weeks.

18 Nov 2010

Dim light at night linked to depression

Exposure to even dim light at night is enough to cause physical changes in the brains of hamsters that may be associated with depression, a new study shows.

18 Nov 2010

Naurex's antidepressant shares efficacy mechanisms with NMDA receptor antagonist ketamine

Naurex Inc., a company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported that data presented at Neuroscience 2010 show that GLYX-13, its clinical-stage candidate for the treatment of depression, shares key mechanistic features associated with the antidepressant efficacy of the NMDA receptor antagonist ketamine.

18 Nov 2010